Also known as: Adcetris
Adcetris is the brand name for brentuximab vedotin, a CD30-directed antibody-drug conjugate used across multiple CD30-positive lymphoid malignancies. Labeling includes adult and selected pediatric classical Hodgkin lymphoma settings, systemic anaplastic large cell lymphoma/peripheral T-cell lymphoma contexts, cutaneous CD30-positive disease, and relapsed/refractory LBCL combination use. It is administered intravenously and has an initial U.S. approval in 2011.
The FDA has approved nivolumab with chemotherapy for pediatric and adult Hodgkin lymphoma patients aged 12+, based on clinical trial data showing improved survival. Separately, the agency cleared investigational new drug applications for FG001 for brain cancer surgery visualization and FRF-001 gene therapy for FOXG1 syndrome, allowing both to proceed to clinical trials.
Pfizer reported positive Phase 3 trial results for BRAFTOVI combination therapy in metastatic colorectal cancer and received FDA Priority Review for HYMPAVZI expansion to hemophilia patients including children.
